Mufg Securities Emea PLC Gilead Sciences, Inc. Transaction History

Mufg Securities Emea PLC

$2.23 Billion
Q2 2024

A detailed history of Mufg Securities Emea PLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mufg Securities Emea PLC holds 192,706 shares of GILD stock, worth $16.1 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares

192,706

Previous 4,031 4680.6%

Holding current value

$16.1 Million

Previous $295,000 4381.69%

% of portfolio

0.59%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$63.15 - $72.88 $11.9 Million - $13.8 Million	188,675 Added 4680.6%	192,706 $13.2 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $28,846 - $35,177	403 Added 11.11%	4,031 $295,000
Q4 2023 Feb 12, 2024	SELL	$73.27 - $83.09 $93,419 - $105,939	-1,275 Reduced 26.0%	3,628 $293,000
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $75,049 - $81,880	1,015 Added 26.11%	4,903 $367,000
Q2 2023 Aug 03, 2023	SELL	$76.01 - $86.7 $52,826 - $60,256	-695 Reduced 15.16%	3,888 $299,000
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $277,542 - $316,207	3,590 Added 361.53%	4,583 $380,000
Q4 2022 Jan 24, 2023	SELL	$62.32 - $89.47 $362,702 - $520,715	-5,820 Reduced 85.42%	993 $85,000
Q3 2022 Nov 09, 2022	SELL	$59.54 - $68.01 $93,477 - $106,775	-1,570 Reduced 18.73%	6,813 $420,000
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $77,922 - $87,763	-1,350 Reduced 13.87%	8,383 $518,000
Q1 2022 May 10, 2022	SELL	$57.92 - $72.58 $886,176 - $1.11 Million	-15,300 Reduced 61.12%	9,733 $579,000
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $77.7 Million - $88.2 Million	-1,198,309 Reduced 97.95%	25,033 $1.82 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $13.9 Million - $15 Million	205,573 Added 20.2%	1,223,342 $85.5 Million
Q2 2021 Jul 19, 2021	SELL	$63.47 - $69.35 $8.06 Million - $8.81 Million	-127,000 Reduced 11.09%	1,017,769 $70.1 Million
Q1 2021 May 11, 2021	BUY	$60.0 - $68.46 $10.2 Million - $11.7 Million	170,825 Added 17.54%	1,144,769 $74 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $14.5 Million - $16.5 Million	255,944 Added 35.65%	973,944 $56.7 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $3.78 Million - $4.75 Million	60,829 Added 9.26%	718,000 $45.4 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $2.33 Million - $2.7 Million	32,171 Added 5.15%	657,171 $50.6 Million
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $10.3 Million - $13.2 Million	-165,000 Reduced 20.89%	625,000 $46.7 Million
Q4 2019 Feb 11, 2020	BUY	$61.62 - $67.78 $30.1 Million - $33.1 Million	488,370 Added 161.91%	790,000 $51.3 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $15.2 Million - $17.1 Million	-246,100 Reduced 44.93%	301,630 $20.4 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $19 Million - $21.3 Million	304,450 Added 125.14%	547,730 $35.6 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $3.77 Million - $4.92 Million	62,257 Added 34.39%	243,280 $15.2 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $2.29 Million - $2.54 Million	32,187 Added 21.63%	181,023 $14 Million
Q2 2018 Aug 01, 2018	SELL	$64.88 - $75.68 $11.3 Million - $13.2 Million	-174,144 Reduced 53.92%	148,836 $10.5 Million
Q1 2018 May 01, 2018	SELL	$72.84 - $88.8 $12.8 Million - $15.6 Million	-175,600 Reduced 35.22%	322,980 $24.3 Million
Q4 2017 Feb 06, 2018	BUY	$71.15 - $83.52 $28 Million - $32.9 Million	393,700 Added 375.38%	498,580 $35.7 Million
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $7.56 Million - $8.96 Million	104,880	104,880 $8.5 Million

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Securities Emea PLC with notifications on news.

Account

Mufg Securities Emea PLC Gilead Sciences, Inc. Transaction History